Skip to main content
. 2015 Feb 3;6(14):12421–12435. doi: 10.18632/oncotarget.3043

Figure 6. Effect of p38 MAPK inactivation on SFK inhibitor-induced RMS cell differentiation.

Figure 6

(A) Representative micrographs of RD and RH30 cells stained with hematoxylin and eosin 6 days after treatment with the p38 MAPK inhibitor SB203580 and/or SI221 or DMSO, as a control. Original magnification: 40X. (B) A representative western blotting analysis of myogenin in RD and RH30 cell lines 6 days after treatment with SB203580 and/or SI221 or DMSO. An anti-β-actin antibody was used for a loading control. (C) Representative micrographs of RD and RH30 cells treated with SB203580 and/or SI221 or DMSO and analysed by immunofluorescence upon staining with an antibody against myosin heavy chain (MYH) and the fluorescent nuclear stain DAPI 6 days after treatment. Original magnification: 40X.